Corcept Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CORT and other ETFs, options, and stocks.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.

CEO

Joseph K. Belanoff

CEOJoseph K. Belanoff

Employees

500

Employees500

Headquarters

Redwood City, California

HeadquartersRedwood City, California

Founded

1998

Founded1998

Employees

500

Employees500

CORT Key Statistics

Market cap

7.85B

Market cap7.85B

Price-Earnings ratio

60.46

Price-Earnings ratio60.46

Dividend yield

—

Dividend yield—

Average volume

3.26M

Average volume3.26M

High today

$78.00

High today$78.00

Low today

$72.59

Low today$72.59

Open price

$77.60

Open price$77.60

Volume

2.54M

Volume2.54M

52 Week high

$117.33

52 Week high$117.33

52 Week low

$20.84

52 Week low$20.84

CORT News

TipRanks 3d

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Pipeline and key...

TipRanks 4d

Corcept Therapeutics price target raised to $142 from $130 at Canaccord

Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $142 from $130 and keeps a Buy rating on the shares. The firm’s target changed follow...

Simply Wall St 5d

Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip

recently announced successful results from its ROSELLA trial for relacorilant plus nab-paclitaxel, indicating a notable positive stride in treatment for platinu...

More CORT News

TipRanks 5d

Promising Phase 3 Results and Market Potential Drive Buy Rating for Corcept Therapeutics

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Corcept Therapeutics (CORT – Research Report) and increased the price target to $...